SCHEMBL6284793

SCHEMBL6284793

COC(=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1CC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.43
GAA P10253 1/20 0.42
HSD11B1 P28845 1/20 0.40
CXCR1 P25024 1/20 0.40
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
GSK3B P49841 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.38
CFTR P13569 1/20 0.37
HTR1D P28221 5/20 0.37
HTR1A P08908 4/20 0.37
HTR1B P28222 4/20 0.37
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
ELANE P08246 1/20 0.35
PRTN3 P24158 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904794 0.86 HSD11B1 (0.43) CXCR2HSD11B1CXCR1KDM4EALDH1A1
SCHEMBL5569165 0.81 HSD11B1 (0.47) CXCR2GAAHSD11B1CXCR1KDM4E
SCHEMBL12470804 0.81 CXCR2 (0.46) CXCR2GAAHSD11B1CXCR1KDM4E
SCHEMBL5703731 0.80 CDK4 (0.43) GAACDK4CCND1GSK3BKDM4E
SCHEMBL974920 0.79 HSD11B1 (0.45) CXCR2GAAHSD11B1CXCR1KDM4E
SCHEMBL3901811 0.79 HSD11B1 (0.45) CXCR2GAAHSD11B1CXCR1KDM4E
SCHEMBL3537593 0.79 CA12 (0.57) CXCR2GAAHSD11B1ALDH1A1HPGD
SCHEMBL7447898 0.78 ALDH1A1 (0.46) CDK4CCND1GSK3BALDH1A1HPGD
SCHEMBL3901554 0.78 CFTR (0.44) CXCR2HSD11B1CXCR1KDM4ECFTR
SCHEMBL3187945 0.78 KMT2A (0.45) CXCR2GAAHSD11B1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215594-A1 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-29 US disclosed
US-6919371-B2 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists BAYER PHARMACEUTICALS CORPORATION (US) 2005-07-19 US disclosed
EP-1389202-B1 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS BAYER PHARMACEUTICALS CORP (US) 2004-09-29 EP disclosed
US-20040072828-A1 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists BAYER PHARMACEUTICALS CORPORATION 2004-04-15 US disclosed
US-6660752-B2 Adrenergic blocking agents BAYER PHARMACEUTICALS CORPORATION 2003-12-09 US disclosed
US-20030078260-A1 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists BAYER PHARMACEUTICALS CORPORATION 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215594-A1 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists ADRB3, ADRB2, ADRB1 CXCR2 1225/4885GAA 3930/4885HSD11B1 417/4885
US-20040072828-A1 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists ADRB3, ADRB2, ADRB1 CXCR2 1225/4885GAA 3930/4885HSD11B1 417/4885
US-20030078260-A1 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists ADRB3, ADRB2, ADRB1 CXCR2 1225/4885GAA 3930/4885HSD11B1 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.